Graves' disease development during sizofiran treatment.
It has been reported that various types of immunoactivators can induce Graves' disease. We describe here a case of Graves' disease during treatment with sizofiran, an immunoactivator. A 42-year-old woman who had previously been in an euthyroid state with Hashimoto's thyroiditis, experienced thyrotoxicosis during continuous administration of sizofiran as immunotherapy for endometrial carcinoma. Since the TSH receptor-antibody was positive, and a thyroid scintigram showed diffuse goiter and high uptake, she was diagnosed as having Graves' disease. It is suggested that the administration of sizofiran may be one of the triggers of Graves' disease.
Morita
Shigeki
S
Internal Medicine, Japanese Red Cross-Nagasaki Atomic Bomb Hospital, Nagasaki.
Ueda
Yasuo
Y
D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects; D005260:Female; D006111:Graves Disease / Q000139:chemically induced*; D006801:Humans; D012566:Sizofiran / Q000009:adverse effects*
D000972:Antineoplastic Agents, Phytogenic; D012566:Sizofiran